HK1007495A1 - Low toxicity drug-lipid systems - Google Patents

Low toxicity drug-lipid systems

Info

Publication number
HK1007495A1
HK1007495A1 HK98106740A HK98106740A HK1007495A1 HK 1007495 A1 HK1007495 A1 HK 1007495A1 HK 98106740 A HK98106740 A HK 98106740A HK 98106740 A HK98106740 A HK 98106740A HK 1007495 A1 HK1007495 A1 HK 1007495A1
Authority
HK
Hong Kong
Prior art keywords
lipid
compositions
hdlcs
drug
lipid complexes
Prior art date
Application number
HK98106740A
Other languages
English (en)
Inventor
Lawrence Bonl
Anthony G Durning
Pieter R Cullis
Andrew S Janoff
John J Kearns
Robert Klimchak
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27361805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1007495(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of HK1007495A1 publication Critical patent/HK1007495A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03BAPPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B2227/00Photographic printing apparatus
    • G03B2227/32Projection printing apparatus, e.g. enlarging apparatus, copying camera
    • G03B2227/325Microcapsule copiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Vehicle Step Arrangements And Article Storage (AREA)
  • Catalysts (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
HK98106740A 1987-03-05 1998-06-25 Low toxicity drug-lipid systems HK1007495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2215787A 1987-03-05 1987-03-05
US6990887A 1987-07-06 1987-07-06
US7930987A 1987-07-29 1987-07-29

Publications (1)

Publication Number Publication Date
HK1007495A1 true HK1007495A1 (en) 1999-04-16

Family

ID=27361805

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98106740A HK1007495A1 (en) 1987-03-05 1998-06-25 Low toxicity drug-lipid systems

Country Status (20)

Country Link
EP (1) EP0282405B2 (fr)
KR (1) KR970002870B1 (fr)
CN (1) CN1044093C (fr)
AT (1) ATE118169T1 (fr)
AU (1) AU622405B2 (fr)
CA (1) CA1338701C (fr)
DE (1) DE3852961T3 (fr)
DK (1) DK176010B1 (fr)
ES (1) ES2070131T5 (fr)
FI (1) FI102724B (fr)
GR (1) GR3015916T3 (fr)
HK (1) HK1007495A1 (fr)
IE (1) IE67152B1 (fr)
IL (1) IL85607A (fr)
LU (1) LU88684I2 (fr)
NL (1) NL990004I1 (fr)
NO (4) NO179995C (fr)
NZ (1) NZ223660A (fr)
PT (1) PT86913B (fr)
WO (1) WO1988006443A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5830498A (en) * 1987-10-16 1998-11-03 Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
DE69026820T2 (de) * 1989-03-31 1996-11-28 Univ California Zubereitung von liposomen- und lipid-komplexzusammensetzungen
US5188951A (en) * 1990-04-17 1993-02-23 The Liposome Company, Inc. Enzymatic synthesis of soluble phosphatides from phospholipids
DE4108902A1 (de) * 1990-08-06 1992-02-13 Nattermann A & Cie Wasserhaltiges liposomensystem
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
US5534502A (en) * 1990-11-06 1996-07-09 Nippon Shinyaku Co. Ltd. Process for producing fat emulsion
EP0556392A4 (fr) * 1990-11-06 1994-03-17 Nippon Shinyaku Co Ltd Procede de production d'une emulsion grasse.
WO1993003737A1 (fr) * 1991-08-14 1993-03-04 Liposome Technology, Inc. Procede de traitement contre le vih avec de l'amphotericine b a faible toxicite
ATE210966T1 (de) * 1993-05-21 2002-01-15 Liposome Co Inc Reduzierung von durch liposome induzierte physiologischen gegenreaktionen
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
EP2007355A2 (fr) * 2005-12-08 2008-12-31 Wyeth a Corporation of the State of Delaware Compositions liposomales
KR101132626B1 (ko) * 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
AU2010359346B2 (en) 2010-08-20 2015-01-29 Dr. Reddy's Laboratories Sa Phospholipid depot
WO2012054447A2 (fr) 2010-10-22 2012-04-26 Dr. Reddy's Laboratories, Inc. Utilisation d'un dépôt visqueux de phospholipides stable pendant le stockage pour traiter les plaies
WO2013168167A1 (fr) 2012-05-10 2013-11-14 Painreform Ltd. Préparations de dépôt d'un principe actif hydrophobe et procédés de préparation associés
US10799456B2 (en) 2015-06-15 2020-10-13 University Of Washington Multiple drug lipid nanoparticle composition and related methods for extended drug levels in blood and lymph tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4436746A (en) * 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
IL78929A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration

Also Published As

Publication number Publication date
FI102724B1 (fi) 1999-02-15
IE880600L (en) 1988-09-05
AU1799088A (en) 1988-09-26
FI102724B (fi) 1999-02-15
IE67152B1 (en) 1996-03-06
NO179995C (no) 1997-01-29
NZ223660A (en) 1990-11-27
PT86913A (pt) 1989-03-30
CN88101864A (zh) 1988-09-28
NO179995B (no) 1996-10-21
AU622405B2 (en) 1992-04-09
DE3852961T2 (de) 1995-07-06
NO884391L (no) 1988-11-24
EP0282405B1 (fr) 1995-02-08
DK98089D0 (da) 1989-03-01
NO180147C (no) 1997-02-26
EP0282405B2 (fr) 1998-07-22
GR3015916T3 (en) 1995-07-31
DK98089A (da) 1989-03-01
ATE118169T1 (de) 1995-02-15
DE3852961T3 (de) 1998-12-24
LU88684I2 (fr) 1996-04-29
IL85607A0 (en) 1988-08-31
CA1338701C (fr) 1996-11-12
KR970002870B1 (ko) 1997-03-12
FI894161A0 (fi) 1989-09-04
ES2070131T3 (es) 1995-06-01
KR890700341A (ko) 1989-04-24
NO884391D0 (no) 1988-10-04
DE3852961D1 (de) 1995-03-23
NO1998013I1 (no) 1998-03-25
ES2070131T5 (es) 1998-10-01
WO1988006443A1 (fr) 1988-09-07
DK176010B1 (da) 2005-11-28
NO944071L (no) 1988-11-24
EP0282405A3 (en) 1989-01-04
IL85607A (en) 1992-08-18
PT86913B (pt) 1993-07-30
EP0282405A2 (fr) 1988-09-14
CN1044093C (zh) 1999-07-14
NL990004I1 (nl) 1999-04-01
NO944071D0 (no) 1994-10-26
NO1998012I1 (no) 1998-03-25
NO180147B (no) 1996-11-18

Similar Documents

Publication Publication Date Title
IL85607A0 (en) Low toxicity drug-lipid systems
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
CA2121345A1 (fr) Compositions de sels d'antibiotiques oligosaccharidiques lipophiles
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
AU617998B2 (en) Anticoccidial composition
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
MY101079A (en) Pharmaceutical formulation for the treatment of bacterial infections.
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
Olay et al. Experimental Staphylococcus aureus osteomyelitis treated with fosfomycin and cephazolin: Single and combined therapy.
Dellamonica et al. Evaluation of rifampicin combined with a synergic antibiotic in severe staphylococcal infection. Report of selection of resistant mutants in seven cases.
CA2080040A1 (fr) Methodes de prevention d'infections mycobacteriennes par administration de rifabutine
CA2013226A1 (fr) Derives de cephalosporine et procede de preparation
EP0281092A3 (fr) Dérivés de céphalosporine et procédé pour leur préparation
CA2564377A1 (fr) Cetolides substitues en 6-o possedant une activite antibacterienne

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080303